4.49
+0.21(+4.91%)
Currency In USD
Address
1400 Sierra Point Parkway
Brisbane, CA 94005
United States of America
Phone
650 822 5500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
106
First IPO Date
July 24, 2020
| Name | Title | Pay | Year Born |
| Mr. Douglas E. Love Esq., J.D. | Chief Executive Officer, President & Director | 1.01M | 1967 |
| Mr. Michael Overdorf M.B.A. | Executive Vice President & Chief Business Officer | 580,469 | 1970 |
| Ms. Jennifer Lew CPA | Executive Vice President, Chief Financial Officer & Corporate Secretary | 624,195 | 1973 |
| Dr. Ted Yednock Ph.D. | Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 714,668 | 1958 |
| Dr. Jamie Dananberg M.D. | Executive Vice President & Chief Medical Officer | 715,233 | 1958 |
| Dr. Dean R. Artis Ph.D. | Chief Scientific Officer & Executive Vice President | 797,380 | 1961 |
| Mr. Henk-Andre Kroon M.D. | Senior Vice President of Translational Medicine | 0 | N/A |
| Mr. Shikhar Agarwal M.B.A. | Senior Vice President & Head of Commercial | 0 | N/A |
| Dr. Sunil Mehta Pharm.D. | Senior Vice President of Medical Affairs | 0 | N/A |
| Dr. Lloyd Clark M.D. | Senior Vice President of Ophthalmology Strategy & Innovation | 0 | N/A |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
